Leandro Güttlein, María R Luca, Federico Esteso, Cristóbal Fresno, Javier Mariani, Mercedes Otero Pizarro, Esteban Brest, Solange Starapoli, Kevin Kreimberg, Paula Teves, Andrea Mendoza Bertelli, María R Girotti, Ruben Salanova, Juan M O'Connor
Objective: To analyze the frequency of KRAS, NRAS and BRAF hotspot mutations in circulating tumor DNA (ctDNA) from patients with metastatic colorectal cancer (mCRC). Methods: Observational, descriptive and retrospective study in mCRC patients with available ctDNA-based genotype of KRAS , NRAS and BRAF . Results: The frequencies of plasma mutations for KRAS , NRAS and BRAF were 34% (± 7), 4% (± 3) and 4% (± 3), respectively. Median overall survival of plasma-tested RAS/BRAF -mutated patients was 26.6 months (95% CI: 14...
August 25, 2022: Future Oncology